WO2001060822A1 - Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece - Google Patents

Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece Download PDF

Info

Publication number
WO2001060822A1
WO2001060822A1 PCT/FR2001/000463 FR0100463W WO0160822A1 WO 2001060822 A1 WO2001060822 A1 WO 2001060822A1 FR 0100463 W FR0100463 W FR 0100463W WO 0160822 A1 WO0160822 A1 WO 0160822A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
compounds
pharmaceutically acceptable
diastereoisomers
Prior art date
Application number
PCT/FR2001/000463
Other languages
English (en)
French (fr)
Other versions
WO2001060822A8 (fr
Inventor
Bernard P. Roques
Marie-Claude Fournie-Zaluski
Nicolas Inguimbert
Hervé Poras
Elizabeth Scalbert
Caroline Bennejean
Pierre Renard
Original Assignee
Institut National De La Recherche Medicale Inserm
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60100388T priority Critical patent/DE60100388T2/de
Priority to EP01907822A priority patent/EP1255757B1/fr
Application filed by Institut National De La Recherche Medicale Inserm, Les Laboratoires Servier filed Critical Institut National De La Recherche Medicale Inserm
Priority to DK01907822T priority patent/DK1255757T3/da
Priority to US10/203,704 priority patent/US6716852B2/en
Priority to SK1182-2002A priority patent/SK11822002A3/sk
Priority to EA200200807A priority patent/EA005004B1/ru
Priority to JP2001560206A priority patent/JP2003523343A/ja
Priority to MXPA02007973A priority patent/MXPA02007973A/es
Priority to HU0300248A priority patent/HUP0300248A3/hu
Priority to PL01357243A priority patent/PL357243A1/xx
Priority to AU3569801A priority patent/AU3569801A/xx
Priority to CA002400537A priority patent/CA2400537A1/fr
Priority to AU2001235698A priority patent/AU2001235698B2/en
Priority to SI200130016T priority patent/SI1255757T1/xx
Priority to BR0108409-7A priority patent/BR0108409A/pt
Priority to AT01907822T priority patent/ATE243210T1/de
Publication of WO2001060822A1 publication Critical patent/WO2001060822A1/fr
Publication of WO2001060822A8 publication Critical patent/WO2001060822A8/fr
Priority to NO20023893A priority patent/NO323871B1/no
Priority to HK03103031A priority patent/HK1050896A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
PCT/FR2001/000463 2000-02-17 2001-02-16 Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece WO2001060822A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AU3569801A AU3569801A (en) 2000-02-17 2001-02-16 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
PL01357243A PL357243A1 (en) 2000-02-17 2001-02-16 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
CA002400537A CA2400537A1 (fr) 2000-02-17 2001-02-16 Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece
EP01907822A EP1255757B1 (fr) 2000-02-17 2001-02-16 Derives d'aminoacides et leurs utilisation en tant qu'inhibiteurs de la nep, l' ace et l' ece
SK1182-2002A SK11822002A3 (sk) 2000-02-17 2001-02-16 Zlúčeniny na báze aminokyselín a ich použitie ako inhibítorov NEP, ACE a ECE
EA200200807A EA005004B1 (ru) 2000-02-17 2001-02-16 Аминокислотные соединения и их применение в качестве ингибиторов nep, ace и ece
JP2001560206A JP2003523343A (ja) 2000-02-17 2001-02-16 アミノ酸化合物、ならびにｎｅｐ、ａｃｅおよびｅｃｅ阻害剤としてのその使用
MXPA02007973A MXPA02007973A (es) 2000-02-17 2001-02-16 Compuestos de aminoacidos y su uso como inhibidores de nep, ace y ece.
HU0300248A HUP0300248A3 (en) 2000-02-17 2001-02-16 Amino acid derivatives and use thereof as nep, ace and ece inhibitors, process for their preparation and pharmaceutical compositions containing them
DE60100388T DE60100388T2 (de) 2000-02-17 2001-02-16 Aminosäurederivate und deren verwendung als inhibitoren von nep, ace und ece
US10/203,704 US6716852B2 (en) 2000-02-17 2001-02-16 Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors
DK01907822T DK1255757T3 (da) 2000-02-17 2001-02-16 Aminosyreforbindelser og deres anvendelse som inhibitorer for NEP, ACE og ECE
AU2001235698A AU2001235698B2 (en) 2000-02-17 2001-02-16 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
SI200130016T SI1255757T1 (en) 2000-02-17 2001-02-16 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
BR0108409-7A BR0108409A (pt) 2000-02-17 2001-02-16 Derivados de aminoácidos e sua utilização como inibidores da nep, da ace e da ece
AT01907822T ATE243210T1 (de) 2000-02-17 2001-02-16 Aminosäurederivate und deren verwendung als inhibitoren von nep, ace und ece
NO20023893A NO323871B1 (no) 2000-02-17 2002-08-16 Aminosyreforbindelser og deres anvendelse som NEP-, ACE- og ECE-inhibitorer
HK03103031A HK1050896A1 (en) 2000-02-17 2003-04-29 Amino acid derivatives and use thereof as nep, aceand ece inhibitors.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/01937 2000-02-17
FR0001937A FR2805259B1 (fr) 2000-02-17 2000-02-17 Nouveaux derives d'aminoacides n-mercaptoacyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
WO2001060822A1 true WO2001060822A1 (fr) 2001-08-23
WO2001060822A8 WO2001060822A8 (fr) 2001-09-27

Family

ID=8847077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000463 WO2001060822A1 (fr) 2000-02-17 2001-02-16 Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece

Country Status (25)

Country Link
US (1) US6716852B2 (no)
EP (1) EP1255757B1 (no)
JP (1) JP2003523343A (no)
KR (1) KR100491605B1 (no)
CN (1) CN1186344C (no)
AR (1) AR029468A1 (no)
AT (1) ATE243210T1 (no)
AU (2) AU2001235698B2 (no)
BR (1) BR0108409A (no)
CA (1) CA2400537A1 (no)
CZ (1) CZ20022811A3 (no)
DE (1) DE60100388T2 (no)
DK (1) DK1255757T3 (no)
EA (1) EA005004B1 (no)
ES (1) ES2202279T3 (no)
FR (1) FR2805259B1 (no)
HK (1) HK1050896A1 (no)
HU (1) HUP0300248A3 (no)
MX (1) MXPA02007973A (no)
NO (1) NO323871B1 (no)
PL (1) PL357243A1 (no)
PT (1) PT1255757E (no)
SK (1) SK11822002A3 (no)
WO (1) WO2001060822A1 (no)
ZA (1) ZA200206221B (no)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds
US9844539B2 (en) 2007-07-17 2017-12-19 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
FR2931151A1 (fr) * 2008-05-13 2009-11-20 Pharmaleads Soc Par Actions Si Nouveaux derives d'amino-acides, leur procede de preparation et leur utilisation therapeutique
BR112012012156A2 (pt) 2009-11-06 2015-09-08 Plexxikon Inc compostos e métodos para modulação de cinase, e indicações para esta
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449523A1 (en) * 1990-03-22 1991-10-02 E.R. SQUIBB & SONS, INC. Mercapto- or acylthio-trifluoromethyl amide derivatives and their use
WO1997024341A1 (en) * 1995-12-28 1997-07-10 Zambon Group S.P.A. Thiol derivatives with metallopeptidase (ace/nep) inhibitory activity
WO1997032874A1 (fr) * 1996-03-04 1997-09-12 Hoechst Marion Roussel Nouveaux derives soufres comportant une liaison amide, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449523A1 (en) * 1990-03-22 1991-10-02 E.R. SQUIBB & SONS, INC. Mercapto- or acylthio-trifluoromethyl amide derivatives and their use
WO1997024341A1 (en) * 1995-12-28 1997-07-10 Zambon Group S.P.A. Thiol derivatives with metallopeptidase (ace/nep) inhibitory activity
WO1997032874A1 (fr) * 1996-03-04 1997-09-12 Hoechst Marion Roussel Nouveaux derives soufres comportant une liaison amide, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844539B2 (en) 2007-07-17 2017-12-19 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10426760B2 (en) 2007-07-17 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US11337976B2 (en) 2011-02-07 2022-05-24 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds

Also Published As

Publication number Publication date
AU2001235698B2 (en) 2005-02-17
KR100491605B1 (ko) 2005-05-27
BR0108409A (pt) 2003-03-11
WO2001060822A8 (fr) 2001-09-27
ES2202279T3 (es) 2004-04-01
AR029468A1 (es) 2003-07-02
CN1400974A (zh) 2003-03-05
US6716852B2 (en) 2004-04-06
CN1186344C (zh) 2005-01-26
DE60100388T2 (de) 2004-05-19
KR20020072581A (ko) 2002-09-16
US20030055086A1 (en) 2003-03-20
EP1255757B1 (fr) 2003-06-18
PT1255757E (pt) 2003-10-31
SK11822002A3 (sk) 2003-03-04
NO20023893L (no) 2002-08-16
EA200200807A1 (ru) 2002-12-26
EA005004B1 (ru) 2004-10-28
DK1255757T3 (da) 2003-10-13
NO323871B1 (no) 2007-07-16
NO20023893D0 (no) 2002-08-16
EP1255757A1 (fr) 2002-11-13
ZA200206221B (en) 2003-08-20
ATE243210T1 (de) 2003-07-15
CA2400537A1 (fr) 2001-08-23
FR2805259A1 (fr) 2001-08-24
HUP0300248A2 (hu) 2003-06-28
HK1050896A1 (en) 2003-07-11
DE60100388D1 (de) 2003-07-24
JP2003523343A (ja) 2003-08-05
PL357243A1 (en) 2004-07-26
HUP0300248A3 (en) 2005-07-28
AU3569801A (en) 2001-08-27
CZ20022811A3 (cs) 2003-01-15
MXPA02007973A (es) 2005-10-05
FR2805259B1 (fr) 2002-03-29

Similar Documents

Publication Publication Date Title
EP0557171B1 (fr) Azaindoles, procédés de préparation et médicaments les contenant
EP0581939B1 (fr) Derives du n-sulfonyl-2-oxoindole ayant une affinite pour les recepteurs de la vasopressine et/ou de l'ocytocine
WO2002042269A1 (fr) Derives de 3-aroylindole et leur utilisation en tant qu'agonistes des recepteurs cb2
CH672637A5 (no)
EP1255757B1 (fr) Derives d'aminoacides et leurs utilisation en tant qu'inhibiteurs de la nep, l' ace et l' ece
EP0429344B1 (fr) Dérivés de la pyridazine, procédé de préparation et compositions pharmaceutiques en contenant
EP0309324A1 (fr) Procédé de synthèse d'alpha amino N alkyles et de leurs esters. Application à la synthèse de carboxyalkyl dipeptides
EP0620221A1 (fr) 5-Acylamino 1,2,4-thiadiazoles comme antagonistes ou agonistes de la cholécystokinine
EP1420028A2 (fr) Procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
WO1995001334A1 (fr) Composes indoliques derives d'arylamines comme ligands selectifs des recepteurs 5ht1d et 5ht¿1b?
FR2758329A1 (fr) Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
EP0527079A1 (fr) N-(isoquinolein-5 YL) sulfonyl azacycloalcanes, leur procédé de préparation et les compositions pharmaceutiques les contenant
FR2771095A1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2519982A1 (fr) Nouveaux derives de l'indoline, leur preparation et leur utilisation comme medicaments
EP0275762B1 (fr) Dérivés de l'indole carboxamide ainsi que leurs sels, procédé et intermédiaires de préparation, application à titre de médicaments de ces dérivés et compositions les renfermant
WO1999006376A1 (fr) Nouvelles sulfonamides derivees d'anilines substituees utiles comme medicaments
EP1367063B1 (fr) Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
EP1367062B1 (fr) Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
FR2543952A1 (fr) Composes hydrocarbones heterocycliques appartenant aux series indoliques et leur application pharmacologique
CH620678A5 (en) Process for the preparation of a derivative of piperidine
BE895586A (fr) Nouveaux derives de l'indoline, leur preparation et leur utilisation comme medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 34/2001 UNDER (51) REPLACE THE EXISTING SYMBOLS BY "C07D209/20, A61K 31/33, A61P 43/00, C07D215/14, 471/04, 333/60, 233/54, 213/54, 219/02 // (C07D471/04, 221:00, 209:00)"

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001907822

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/06221

Country of ref document: ZA

Ref document number: 200206221

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 10203704

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001235698

Country of ref document: AU

Ref document number: 1020027010552

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 560206

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 018050921

Country of ref document: CN

Ref document number: 11822002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2400537

Country of ref document: CA

Ref document number: PA/a/2002/007973

Country of ref document: MX

Ref document number: PV2002-2811

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 200200807

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 521394

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020027010552

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001907822

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-2811

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001907822

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 521394

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521394

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 1020027010552

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2001235698

Country of ref document: AU